SpineThera, Inc., a company specializing in long-acting injectable technologies, has announced a new partnership with Mayo Clinic to develop treatments aimed at improving outcomes for those with substance abuse disorders.

The opioid epidemic continues to be a major public health challenge, impacting millions worldwide. There is a critical need for effective treatment options that enhance patient outcomes, increase access to supervised care, and reduce risks associated with existing treatments.

This project will be led by SpineThera's CEO, Jeff Missling, and Dr. Tyler Oesterle, who chairs the Addiction Medicine department at Mayo Clinic.

Jeff Missling commented on the collaboration, saying, “SpineThera’s novel long-acting injectable technology has potential across various therapeutic areas. We are excited to strategically enter the substance abuse disorder treatment field through this partnership. Despite the availability of several approved medications for opioid use disorder, the crisis persists, and we are eager to contribute solutions.”

By leveraging SpineThera’s innovative technology alongside Mayo Clinic’s expertise in addiction medicine, this collaboration aims to develop more effective and accessible treatment options. SpineThera is committed to addressing this critical healthcare challenge and improving the lives of individuals affected by substance abuse disorders.

Mayo Clinic will benefit financially from the technology referenced in this release, using any generated revenue to support its not-for-profit mission in patient care, education, and research.

 

Source: businesswire.com

Report Abuse